PsychoGenics Obtains an Exclusive License to the rTg4510 Tauopathy Mouse Model
TARRYTOWN, N.Y.--(BUSINESS WIRE)--PsychoGenics Inc. announced today that it has obtained licenses to the rTg4510 tauopathy mouse from Mayo Clinic and TET Systems GmbH & Co. KG (TET Systems). The rTg4510 mouse expresses the P301L mutation in the tau gene associated with frontotemporal dementia and Parkinsonism linked to chromosome 17. Transgene expression in this model is induced via the tetracycline-operon responsive element (licensed from TET Systems) and is reversibly suppressed after treatment with doxycycline.
“Our agreement permits us to offer our customers behavioral and non-behavioral testing in the rTg4510 mouse model, providing a valuable tool in the quest for novel treatments for devastating tau-associated neurodegenerative diseases.”
The rTg4510 mice were developed by Drs. Karen K. Hsiao Ashe, Jada Lewis, and Michael Hutton. The mice exhibit many salient characteristics of hereditary human dementia in an age-dependent manner including cognitive impairment, motor deficits, the presence of neurofibrillary tangles (NFTs), and neuronal loss in the forebrain. Collectively, these data describe a novel transgenic mouse that closely mimics human tauopathy and may represent an important model for the future study of tau-related neurodegenerative disease including Alzheimer’s disease.
“This rTg4510 mouse model has been extensively characterized by PsychoGenics and many other labs and we are delighted to be able to offer it to our clients to help identify treatments for Tau related disorders. Using our proprietary behavioral testing platforms and other capabilities, we have confirmed the phenotype described by other labs. In addition to a pronounced nocturnal hyperactivity, we found deficits in the acquisition of two different visual memory tasks,” remarked Dr. Emer Leahy, President and CEO of PsychoGenics. “Our agreement permits us to offer our customers behavioral and non-behavioral testing in the rTg4510 mouse model, providing a valuable tool in the quest for novel treatments for devastating tau-associated neurodegenerative diseases.”
PsychoGenics is a leader in in vivo phenotypic drug discovery. The Company applies its proprietary technology platforms in partnership with pharmaceutical and biotechnology companies to discover the next generation of drugs for neuropsychiatric disorders. PsychoGenics' capabilities also include standard behavioral testing, electrophysiology, molecular biology, and state-of-the-art microdialysis and dendritic spine analysis. In addition, the company offers a variety of in-licensed transgenic mouse models that support research in areas such as Huntington’s disease, Autism spectrum disorders, psychosis/schizophrenia, Parkinson’s disease, Spinal Muscular Atrophy (SMA), Muscular Dystrophy and other muscle disorders. For more information on PsychoGenics Inc. visit www.psychogenics.com.